Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Consun Pharmaceutical GroupCPHGF +9.09%55 Days Payable is 52.72 as of Dec. 2025, which is 13% above its 10-year median of 46.57. GuruFocus rates CPHGF with a GF Score™ of 55/100 and a GF Value™ of $0.60 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 925 Drug Manufacturers companies, Consun Pharmaceutical Group ranks worse than 75.46% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's Days Payable distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's Days Payable falls into.
Consun Pharmaceutical Group Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (CPHGF) has a Days Payable of 52.72 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Consun Pharmaceutical Group and its competitors. This is 13% above median its historical median of 46.57. Over the past decade, Consun Pharmaceutical Group's Days Payable has ranged from 39.38 to 71.46. According to the industry distribution chart, Consun Pharmaceutical Group ranks #698 out of 925 companies in the Drug Manufacturers industry, placing it in the top 75.5%.
Is Consun Pharmaceutical Group's Days Payable too high?
Consun Pharmaceutical Group's current Days Payable of 52.72 is 13% above median its 10-year median of 46.57. Over the past 10 years, this metric has ranged from a low of 39.38 to a high of 71.46. The Drug Manufacturers industry median Days Payable is 90.38. Consun Pharmaceutical Group's value of 52.72 is 41.7% below this industry median. Based on the distribution chart, Consun Pharmaceutical Group ranks #698 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Consun Pharmaceutical Group has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Consun Pharmaceutical Group's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Consun Pharmaceutical Group ranks #698 out of 925 companies for Days Payable. This places Consun Pharmaceutical Group in the lower half of its industry. The industry median Days Payable is 90.38. Consun Pharmaceutical Group's value of 52.72 is 41.7% below this benchmark. Historically, Consun Pharmaceutical Group's own Days Payable has ranged from 39.38 to 71.46 over the past decade. While the company's 10-year median is 46.57 vs. the industry median of 90.38, Consun Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Consun Pharmaceutical Group's current Days Payable of 52.72 is 41.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Consun Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Consun Pharmaceutical Group's current Days Payable is 52.72, which is 13% above median its own 10-year median of 46.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Consun Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Consun Pharmaceutical Group (CPHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.60, compared to a current price of $1.80 — trading 200% above its estimated fair value. The current Days Payable is 52.72, which is 13% above median its 10-year median of 46.57 and 41.7% below the Drug Manufacturers industry median of 90.38. Consun Pharmaceutical Group's overall GF Score™ is 55/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Consun Pharmaceutical Group (CPHGF), the current Days Payable is 52.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Consun Pharmaceutical Group (CPHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Consun Pharmaceutical Group stock appears to be overvalued.
The current stock price of $1.80 is trading 200% above its estimated GF Value™ of $0.60.
GuruFocus considers Consun Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for CPHGF:
Days Payable: 52.72 (13% above median its 10-year median of 46.57)
GF Value™: $0.60 vs. price of $1.80 (200% above fair value)
Industry Position: 41.7% below the Drug Manufacturers median (#698 of 925)
No single metric tells the full story. See the CPHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
55GF Score
Get the complete analysis for CPHGF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHGF has been successfully added to your 
